Basal cell carcinoma - An overview;Basalzellkarzinome - Ein überblick

Deutsche Medizinische Wochenschrift

Volumn 129, Issue 42, 2004, Pages 2255-2260

  Dissemond, Joachim ^a   Grabbe, S ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENT; BLEOMYCIN; CIDOFOVIR; CISPLATIN; CYTOKERATIN; DICLOFENAC; DNA; DOXORUBICIN; EPIGALLOCATECHIN GALLATE; FLUOROURACIL; GLUTATHIONE; HLA DR4 ANTIGEN; IMIQUIMOD; IMMUNOMODULATING AGENT; INTERFERON; ISOTRETINOIN; PHOTOSENSITIZING AGENT; PROTEIN P53; PSORALEN; RETINOID; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; UNCLASSIFIED DRUG; UREA;

BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; CANCER RADIOTHERAPY; CANCER SURGERY; CARBON DIOXIDE LASER; CRYOTHERAPY; EPILUMINESCENCE MICROSCOPY; HEREDITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KERATINOCYTE; KIDNEY TRANSPLANTATION; LOW LEVEL LASER THERAPY; METASTASIS; NEODYMIUM LASER; OXIDATIVE STRESS; PATHOGENESIS; PHOTODYNAMIC THERAPY; PUVA; REVIEW; RISK FACTOR; ULTRAVIOLET RADIATION; ADULT; COMPARATIVE STUDY; FEMALE; GENETICS; IMMUNE DEFICIENCY; IMMUNOTHERAPY; MALE; MIDDLE AGED; PATHOLOGY; PHOTOCHEMOTHERAPY; PROGNOSIS; SKIN; SKIN TUMOR;

ADULT; CARCINOMA, BASAL CELL; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOTHERAPY; INCIDENCE; MALE; MIDDLE AGED; OXIDATIVE STRESS; PHOTOCHEMOTHERAPY; PROGNOSIS; RISK FACTORS; SKIN; SKIN NEOPLASMS; ULTRAVIOLET RAYS;

EID: 7044284735     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-831875     Document Type: Review

References (50)

1. Alcalay J, Freeman SE, Goldberg LH, Kripke ML, Wolf JE. Decreased excision repair of pyrimidine dimers induced in the skin of basal cell carcinoma patients by simulated solar radiation. J Invest Dermatol 1990; 94: 502
2. Asada M, Korge B, Almeida H et al. Solid basal cell epithelioma possibly originates from the lower part of the outer root sheath. Zbl Haut 1991; 158: 2320
3. Bath FJ, Bong J, Perkins W, Williams HC. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 2003; 2: CD003412
4. Blum A, Metzler G, Hofmann-Wellenhof R, Soyer HP, Garbe C, Bauer J. Correlation between dermoscopy and histopathology in pigmented and non-pigmented skin tumours. Hautarzt 2003; 54: 279-291
5. Bavinck JN, Bastiaens MT, Marugg ME et al. Further evidence for an association of HLA-DR7 with basal cell carcinoma on the tropical island of Saba. Arch Dermatol 2000; 136: 1019-1022
6. Breuninger H, Garbe K. Basalazellkarzinom. Hautarzt 1998; 10: S15-19
7. Calista D. Topical 1% cidofovir for the treatment of basal cell carcinoma. Eur J Dermatol 2002; 12: 562-564
8. Czarnecki D, Lewis A, Nicholson I, Tait B. Multiple basal cell carcinomas and HLA frequencies in southern Australia. J Am Acad Dermatol 1991; 24: 559-561
9. Danopoulos ED, Danopoulou IE. Regression of liver cancer with oral urea. Lancet 1974; 1: 132
10. D'Errico M, Calcagnile AS, Corona R et al. p53 mutations and chromosome instability in basal cell carcinomas developed at an early or late age. Cancer Res 1997; 57: 747-752
11. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681-1691
12. George R, Weightman W, Russ GR, Bannister KM, Mathew TH. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol 2002; 43: 269-273
13. Giuffrida TJ, Jimenez G, Nouri K. Histologic cure of basal cell carcinoma treated with cryosurgery. J Am Acad Dermatol 2003; 49: 483-486
14. Greinert R, Volkmer B, Wende A, Voss S, Breitbart EW. Prevention von Hautkrebs. Notwendigkeit, Durchführung und Erfolg. Hautarzt 2003; 54: 1152-1163
15. Kanitakis J, Alhaj-Ibrahim L, Euvrard S, Claudy A, Basal cell carcinomas developing in solid organ transplant recipients: clinicopathologic study of 176 cases. Arch Dermatol 2003; 139: 1133-1137
16. Katiyar SK, Ahmad N, Mukhtar H. Green tea and skin. Arch Dermatol 2000; 136: 989-994
17. Kim KH, Yavel RM, Gross VL, Brody N. Intralesional Interferon alpha-2b in the Treatment of Basal Cell Carcinoma and Squamous Cell Carcinoma: Revisited. Dermatol Surg 2004; 30: 116-120
18. Kopf A. Computer analysis of 3531 basalcell carcinomas of the skin. J Derm 1979; 6: 267-281
19. Kowalzick L, Rogozinski T, Wimheuer R et al. Intralesional recombinant interferon beta-1 a in the treatment of basal cell carcinoma: results of an open-label multicentre study. Eur J Dermatol 2002; 12: 558-561
20. Kumar P, Watson S, Brain AN et al. Incomplete excision of basal cell carcinoma: a prospective multicentre audit. Br J Plast Surg 2002; 55: 616-622
21. Lear JT, Smith AG. Basal cell carcinoma. Postgrad Med J 1997; 73: 538-542
22. Levi F, La Vecchia C, Te VC, Randimbison L, Erler G. Incidence of invasive cancers following basal cell skin cancer. Am J Epidemiol 1998; 147: 722-726
23. Marmur ES, Schmults CD, Goldberg DJ. A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer. Dermatol Surg 2004; 30: 264-271
24. Miller SJ. Biology of basal cell carcinoma (Part I). J Am Acad Dermatol 1991; 24: 1-13
25. Moore JV, Allan E. Pulsed ultrasound measurements of depth and regression of basal cell carcinomas after photodynamic therapy: relationship to probability of 1-year local control. Br J Dermatol 2003; 149: 1035-1040
26. Nagore E, Grau C, Molinero J, Fortea JM. Positive margins in basal cell carcinoma: relationship to clinical features and recurrence risk. A retrospective study of 248 patients. J Eur Acad Dermatol Venereol 2003; 17: 167-170
27. Nékám L. Basalioma adenoides cysticum esete. Orvosi Hetilap 1901; 39: 1-10
28. Nickoloff BJ, Qin JZ, Chaturvedi V, Bacon P, Panella J, Denning MF. Life and death signaling pathways contributing to skin cancer. J Invest Dermatol Symp Proc 2002; 7: 27-35
29. Nijsten TE, Stern RS. The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study. J Invest Dermatol 2003; 121: 252-258
30. Peterson SR, Goldberg LH. New and emerging treatments for nonmelanomas and actinic keratoses. J Drugs Dermatol 2003; 2: 429-432
31. Pfeiffer P, Hansen O, Rose C. Systemic cytotoxic therapy of basal cell carcinoma. A review of the literature. Eur J Cancer 1990; 26: 73-77
32. Pfister R. Antibiotische Behandlung maligner epthelialer Tumoren. Fortschr Med 1977; 12: 784-787
33. Reyman F. Treatment of basal cell carcinoma of the skin with 5-Fluorouracil ointment. A 10-year follow-up study. Dermatologica 1979; 158: 368-372
34. Rhodes LE, de Rie M, Enstrom Y et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol 2004; 140: 17-23
35. Robins W. Chemosurgery: My 15 years of experimence. J Dermatol Surg Oncol 1981; 9: 79-789
36. Rozylo-Kalinowska I, Rozylo TK. Odontogenic keratocyst in Gorlin-Goltz syndrome. Ann Univ Mariae Curie Sklodowska 2002; 57: 79-85
37. Safai B, Good RA. Basal cell carcinoma with metastasis. Review of the literature. Arch Pathol Lab Med 1977; 101: 327-331
38. Schon M, Bong AB, Drewniok C et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003; 95: 1138-1149
39. Seegenschmiedt MH, Oberste-Beulmann S, Lang E, Lang B, Guntrum F, Olschewski T. Strahlentherapie des Basalzellkarzinoms. Strahlenther Onkol 2001; 177: 240-246
40. Smyth I, Narang MA, Evans T et al. Isolation and characterization of human patched 2 (PTCH2), a putative tumour suppressor gene inbasal cell carcinoma and medulloblastoma on chromosome 1p32. Hum Mol Genet 1999; 8: 291-297
41. Spates ST, Jr. Mellette JR, Fitzpatrick J. Metastatic basal cell carcinoma. Dermatol Surg 2003; 29: 650-652
42. Szeimies RM, Landthaler M. Photodynamic therapy and fluorescence diagnosis of skin cancers. Recent Results Cancer Res 2002; 160: 240-245
43. Tangrea JA, Edwards BK, Taylor PR et al. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group. J Natl Cancer Inst 1992; 84: 328-332
44. Thissen MR, Neumann MH, Scheuten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999; 135: 1177-1183
45. Thomas DJ, King AR, Peat BG. Excision margins for nonmelanotic skin cancer. Plast ReconstrSurg 2003; 2: 57-63
46. Tran H, Chen K, Shumack S. Epidemiology and aetiology of basal cell carcinoma. Br J Dermatol 2003; 149: 50-52
47. Van Scott EG, Reinertson RP. The modulating influence of stromal environment on epithelial cells studied in human autotransplants. J Invest Dermatol 1961; 39: 183-189
48. von Domarus H, Stevens PJ. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature. J Am Acad Dermatol 1984; 10: 1043-1060
49. Wallberg P, Skog E. The incidence of basal cell carcinoma in an area of Stockholm County during the period 1971-1980. Acta Derm Venereol 1991; 71: 134-137
50. Zeitouni NC, Oseroff AR, Shieh S. Photodynamic therapy for nonmelanoma skin cancers. Current review and update. Mol Immunol 2003; 39: 1133-1136